A more joined-up approach to procurement criteria is needed in Europe for the biosimilars industry to remain sustainable at a time of rising costs and downwards pressure on pricing, heard attendees at Medicines for Europe’s 18th Biosimilar Medicines Conference in Brussels, Belgium, in early October.
Joined-Up Approach Must Underpin European Biosimilar Procurement
Greater Harmonization Of Procurement Criteria Across Member States Is Called For
A more joined-up approach is needed on European procurement if the biosimilars market is to remain sustainable in the face of pricing and cost pressures, according to a discussion by industry stakeholders at Medicines for Europe’s 18th Biosimilar Medicines Conference.
More from Biosimilars
More from Products
• By
Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.
• By
The US FDA has deemed certain CRO Raptim Research’s in vitro bioequivalence studies as “not acceptable” and raised concerns over its in vivo study methods. Will other agencies follow suit?
• By
Teva should not be able to overturn European fines imposed over a historical “pay-for-delay” arrangement covering Cephalon’s Provigil (modafinil), an advocate general of the CJEU has recommended.